JY
HOWL icon

Jeff Yass’s Werewolf Therapeutics HOWL Stock Holding History

Jeff Yass’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-99,829
Closed -$63.2K – 13560
2025
Q4 		$63.2K Buy
99,829
+6,788
+7% +$8.25K ﹤0.01% 11670
2025
Q3 		$183K Buy
93,041
+13,439
+17% +$18.4K ﹤0.01% 11083
2025
Q2 		$86.8K Buy
79,602
+30,261
+61% +$31.1K ﹤0.01% 11865
2025
Q1 		$48K Buy
49,341
+15,479
+46% +$20.3K ﹤0.01% 11879
2024
Q4 		$50.1K Buy
+33,862
New +$69K ﹤0.01% 11675
2024
Q2 		– Sell
-175,798
Closed -$1.14M – 12535
2024
Q1 		$1.14M Buy
175,798
+161,021
+1,090% +$938K ﹤0.01% 6580
2023
Q4 		$57K Buy
+14,777
New +$37.7K ﹤0.01% 11667
2022
Q1 		– Sell
-11,829
Closed -$141K – 13415
2021
Q4 		$141K Buy
+11,829
New +$179K ﹤0.01% 11862

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.25M AUM 26.51% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Jeff Yass's HOWL Position: Q1 2026 in Review

Jeff Yass sold out of Werewolf Therapeutics (HOWL) in Q1 2026, closing a stake of 99,829 shares — an estimated $63.2K sold.

Jeff Yass first reported a position in HOWL in Q4 2021 and held it in 8 quarters. The position peaked at $1.14M in Q1 2024. 48 funds tracked by Wall St. Rank hold HOWL as of Q1 2026.

  • Jeff Yass reported no remaining Werewolf Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Jeff Yass sold 99,829 Werewolf Therapeutics shares in Q1 2026, an estimated $63.2K.
  • Jeff Yass first reported a position in Werewolf Therapeutics in Q4 2021 and held it in 8 quarters.
  • Jeff Yass's Werewolf Therapeutics position peaked at $1.14M in Q1 2024.
  • 48 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.